This program is supported by an educational grant from Pfizer. It is designed only for healthcare professionals in the United States.
Accreditation: 0.25 AMA PRA Category 1 Credit™
This activity is designed for healthcare professionals in community and academic settings involved in the selection, prescription, and management of first-line targeted therapies for patients with BRAF V600E–mutant mCRC or mNSCLC, including:
- Medical oncologists
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Faculty
Zev A. Wainberg, MD, is Professor of Medicine at the David Geffen School of Medicine at UCLA, where he serves as Co-Director of the UCLA Gastrointestinal (GI) Oncology Program and Director of the Early Phase Clinical Research Program at the UCLA Jonsson Comprehensive Cancer Center.
An internationally recognized expert in gastrointestinal and thoracic cancers, Dr. Wainberg has led and authored numerous clinical trials investigating novel targeted and immunotherapeutic strategies. His research and leadership continue to shape best practices in biomarker-driven care for patients with advanced malignancies.
Continuing Education Information
This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. Pharmacists will be eligible ACPE credit. A statement of participation is available for other healthcare professionals.
Unapproved and/or off-label use disclosure
Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:
-
When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
-
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Disclosures
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr. Zev Wainberg has disclosed financial relationships within the past 24 months with the following ineligible companies: Alligator Therapeutics, Amgen, AstraZeneca, Arcus, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo Company, Eli Lilly and Company, EMD Serono, Roche AG, Genentech, Ipsen, Johnson & Johnson, Merus N.V., Merck, Novartis, Novocure, Pfizer, Servier, Verastem, in consulting roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Wainberg does not intend to reference any unlabeled or unapproved uses of products during the presentation.
CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.
Activity Accreditation for Health Professions
Physicians
AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.
This continuing education activity will expire on 3rd March 2026.
Estimated time to complete this activity: 15 minutes.
Social Media Learning Series: CME Material and Disclosures
This program is supported by an educational grant from Pfizer. It is designed only for healthcare professionals in the United States.
Accreditation: 0.25 AMA PRA Category 1 Credit™
This activity is designed for healthcare professionals in community and academic settings involved in the selection, prescription, and management of first-line targeted therapies for patients with BRAF V600E–mutant mCRC or mNSCLC, including:
Faculty
Zev A. Wainberg, MD, is Professor of Medicine at the David Geffen School of Medicine at UCLA, where he serves as Co-Director of the UCLA Gastrointestinal (GI) Oncology Program and Director of the Early Phase Clinical Research Program at the UCLA Jonsson Comprehensive Cancer Center.
An internationally recognized expert in gastrointestinal and thoracic cancers, Dr. Wainberg has led and authored numerous clinical trials investigating novel targeted and immunotherapeutic strategies. His research and leadership continue to shape best practices in biomarker-driven care for patients with advanced malignancies.
Continuing Education Information
This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. Pharmacists will be eligible ACPE credit. A statement of participation is available for other healthcare professionals.
Unapproved and/or off-label use disclosure
Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:
When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Disclosures
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr. Zev Wainberg has disclosed financial relationships within the past 24 months with the following ineligible companies: Alligator Therapeutics, Amgen, AstraZeneca, Arcus, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo Company, Eli Lilly and Company, EMD Serono, Roche AG, Genentech, Ipsen, Johnson & Johnson, Merus N.V., Merck, Novartis, Novocure, Pfizer, Servier, Verastem, in consulting roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Wainberg does not intend to reference any unlabeled or unapproved uses of products during the presentation.
CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.
Activity Accreditation for Health Professions
Physicians
AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.
This continuing education activity will expire on 3rd March 2026.
Estimated time to complete this activity: 15 minutes.